Claims for Patent: 12,521,369

Summary for Patent: 12,521,369

Title:	Methods of improving renal function
Abstract:	Provided herein are methods of improving kidney function in a subject in need thereof.
Inventor(s):	Philip Thomas Frohlich, Andrew James KING, Chidambaram Ramachandran, Sarah Beth Noonberg
Assignee:	Chinook Therapeutics Inc
Application Number:	US18/523,609
Patent Claims:	1. A method of stabilizing eGFR in a subject, wherein the subject has biopsy-diagnosed IgA nephropathy, comprising administering to the subject from about 0.20 mg to about 1.5 mg of atrasentan, or an equivalent amount of a pharmaceutically acceptable salt thereof. 2. The method of claim 1, wherein the subject has an average eGFR of about 20 to about 90 mL/min/1.73 m2 prior to the first administration of atrasentan, or the pharmaceutically acceptable salt thereof. 3. The method of claim 2, wherein the subject has an average eGFR of about 30 to about 90 mL/min/1.73 m2 prior to the first administration of atrasentan, or the pharmaceutically acceptable salt thereof. 4. The method of claim 3, wherein the subject has an average eGFR of about 20 to about 60 mL/min/1.73 m2 prior to the first administration of atrasentan, or the pharmaceutically acceptable salt thereof. 5. The method of claim 1, wherein the method results in reducing the rate of eGFR decline by at least about 10% after treatment with atrasentan or the pharmaceutically acceptable salt thereof. 6. The method of claim 5, wherein the method results in reducing the rate of eGFR decline by at least about 30% after treatment with atrasentan or the pharmaceutically acceptable salt thereof. 7. The method of claim 6, wherein the method results in reducing the rate of eGFR decline by at least about 50% after treatment with atrasentan or the pharmaceutically acceptable salt thereof. 8. The method of claim 1, comprising administering to the subject from about 0.40 mg to about 0.85 mg of atrasentan, or an equivalent amount of a pharmaceutically acceptable salt thereof. 9. The method of claim 8, comprising administering to the subject about 0.75 mg of atrasentan, or an equivalent amount of a pharmaceutically acceptable salt thereof. 10. The method of claim 1, wherein the subject has not been previously diagnosed with one or more of diabetic nephropathy, HIV/AIDS, or acute kidney failure. 11. The method of claim 1, wherein atrasentan is administered as atrasentan hydrochloride. 12. The method of claim 1, wherein the subject has an average eGFR of at least about 30 mL/min/1.73m2 prior to the first administration of atrasentan, or the pharmaceutically acceptable salt thereof. 13. The method of claim 1, wherein the biopsy-diagnosed IgA nephropathy is primary IgA nephropathy. 14. The method of claim 1, wherein the method treats the subject's IgA nephropathy. 15. The method of claim 9, wherein atrasentan is administered as atrasentan hydrochloride. 16. The method of claim 9, wherein the subject has an average eGFR of at least about 30 mL/min/1.73m2 prior to the first administration of atrasentan, or the pharmaceutically acceptable salt thereof. 17. The method of claim 9, wherein the biopsy-diagnosed IgA nephropathy is primary IgA nephropathy. 18. The method of claim 9, wherein the method treats the subject's IgA nephropathy. 19. The method of claim 9, wherein the method results in reducing the rate of eGFR decline by at least about 10% after treatment with atrasentan or the pharmaceutically acceptable salt thereof. 20. The method of claim 9, wherein the method results in reducing the rate of eGFR decline by at least about 30% after treatment with atrasentan or the pharmaceutically acceptable salt thereof. 21. The method of claim 9, wherein the method results in reducing the rate of eGFR decline by at least about 50% after treatment with atrasentan or the pharmaceutically acceptable salt thereof. 22. The method of claim 9, wherein atrasentan or the pharmaceutically acceptable salt thereof is administered as a tablet once daily. 23. The method of claim 22, wherein the method results in reducing the rate of eGFR decline by at least about 10% after treatment with atrasentan or the pharmaceutically acceptable salt thereof for a duration of about 130 weeks. 24. The method of claim 1, wherein the nephropathy is primary IgA nephropathy and the subject is administered 0.75 mg of atrasentan, or an equivalent amount of a pharmaceutically acceptable salt thereof, once daily in the form of a tablet. 25. The method of claim 1, wherein the nephropathy is primary IgA nephropathy and the subject is administered 0.75 mg of atrasentan, or an equivalent amount of a pharmaceutically acceptable salt thereof, once daily in the form of a tablet, and wherein the method results in reducing the rate of eGFR decline by at least about 10% after treatment with atrasentan or the pharmaceutically acceptable salt thereof. 26. The method of claim 1, wherein the nephropathy is primary IgA nephropathy and the subject is administered 0.75 mg of atrasentan, or an equivalent amount of a pharmaceutically acceptable salt thereof, once daily in the form of a tablet, and wherein the method results in reducing the rate of eGFR decline by at least about 30% after treatment with atrasentan or the pharmaceutically acceptable salt thereof. 27. The method of claim 1, wherein the nephropathy is primary IgA nephropathy and the subject is administered 0.75 mg of atrasentan, or an equivalent amount of a pharmaceutically acceptable salt thereof, once daily in the form of a tablet, and wherein the method results in reducing the rate of eGFR decline by at least about 50% after treatment with atrasentan or the pharmaceutically acceptable salt thereof.